Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$308.71 0.0%	$273.09	$152.30 ▼ $310.22	$40.16B	0.22	931,065 shs	570,555 shs
BIIB Biogen	$126.56 -3.4%	$124.21	$110.04 ▼ $238.00	$19.14B	0.14	1.42 million shs	1.15 million shs
INCY Incyte	$68.81 -3.4%	$62.79	$53.56 ▼ $83.95	$13.11B	0.67	2.05 million shs	2.02 million shs
NBIX Neurocrine Biosciences	$124.88 -0.1%	$113.87	$84.23 ▼ $157.98	$12.31B	0.24	1.14 million shs	807,029 shs

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	-0.02%	+2.07%	+8.20%	+21.81%	+96.26%
BIIB Biogen	-3.42%	-6.59%	+0.77%	-10.51%	-44.11%
INCY Incyte	-3.38%	-1.80%	+8.69%	+14.04%	+9.76%
NBIX Neurocrine Biosciences	-0.10%	+0.09%	+3.19%	+13.21%	-7.69%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALNY Alnylam Pharmaceuticals	4.1756 of 5 stars	2.4	5.0	4.3	2.9	2.5	0.6
BIIB Biogen	4.7266 of 5 stars	4.2	3.0	3.7	3.2	1.7	1.9
INCY Incyte	4.4848 of 5 stars	2.1	4.0	3.1	3.2	2.5	3.1
NBIX Neurocrine Biosciences	4.8922 of 5 stars	4.4	3.0	2.9	2.4	2.5	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALNY Alnylam Pharmaceuticals	2.77	Moderate Buy	$319.58	3.52% Upside
BIIB Biogen	2.38	Hold	$188.19	48.69% Upside
INCY Incyte	2.22	Hold	$74.53	8.32% Upside
NBIX Neurocrine Biosciences	2.86	Moderate Buy	$162.00	29.72% Upside

Current Analyst Ratings Breakdown

Latest NBIX, ALNY, BIIB, and INCY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/16/2025	INCY Incyte	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$75.00 ➝ $107.00
6/12/2025	ALNY Alnylam Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$330.00 ➝ $338.00
6/12/2025	BIIB Biogen	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$115.00
6/12/2025	BIIB Biogen	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$121.00
6/12/2025	BIIB Biogen	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
6/3/2025	INCY Incyte	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
6/3/2025	INCY Incyte	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$61.00
6/2/2025	NBIX Neurocrine Biosciences	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$145.00
5/27/2025	INCY Incyte	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$72.00 ➝ $73.00
5/7/2025	BIIB Biogen	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$207.00 ➝ $169.00
5/6/2025	NBIX Neurocrine Biosciences	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform

(Data available from 6/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALNY Alnylam Pharmaceuticals	$2.25B	17.90	N/A	N/A	$0.52 per share	593.67
BIIB Biogen	$9.68B	1.92	$22.40 per share	5.65	$114.71 per share	1.10
INCY Incyte	$4.24B	3.14	$0.56 per share	122.38	$17.90 per share	3.84
NBIX Neurocrine Biosciences	$2.36B	5.25	$3.39 per share	36.80	$25.58 per share	4.88

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALNY Alnylam Pharmaceuticals	-$278.16M	-$2.09	N/A	346.87	N/A	-11.49%	-510.31%	-6.48%	7/30/2025 (Estimated)
BIIB Biogen	$1.63B	$10.13	12.49	7.67	1.04	15.07%	14.03%	8.32%	7/30/2025 (Estimated)
INCY Incyte	$32.62M	$0.32	215.04	10.52	0.60	0.48%	2.77%	1.77%	7/29/2025 (Estimated)
NBIX Neurocrine Biosciences	$341.30M	$2.95	42.33	19.30	1.28	12.68%	11.81%	8.59%	7/30/2025 (Estimated)

Latest NBIX, ALNY, BIIB, and INCY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/5/2025	Q1 2025	NBIX Neurocrine Biosciences	$0.70	$0.08	-$0.62	$0.08	$587.06 million	$572.60 million
5/1/2025	Q1 2025	ALNY Alnylam Pharmaceuticals	-$0.37	-$0.44	-$0.07	-$0.44	$584.32 million	$594.19 million
5/1/2025	Q1 2025	BIIB Biogen	$3.26	$3.02	-$0.24	$1.64	$2.25 billion	$2.43 billion
4/29/2025	Q1 2025	INCY Incyte	$1.01	$1.16	+$0.15	$0.80	$996.17 million	$1.05 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALNY Alnylam Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BIIB Biogen	N/A	N/A	N/A	N/A	N/A
INCY Incyte	N/A	N/A	N/A	N/A	N/A
NBIX Neurocrine Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALNY Alnylam Pharmaceuticals	15.27	2.78	2.71
BIIB Biogen	0.27	1.35	0.90
INCY Incyte	0.01	1.97	1.94
NBIX Neurocrine Biosciences	N/A	3.40	3.28

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALNY Alnylam Pharmaceuticals	92.97%
BIIB Biogen	87.93%
INCY Incyte	96.97%
NBIX Neurocrine Biosciences	92.59%

Insider Ownership

Company	Insider Ownership
ALNY Alnylam Pharmaceuticals	1.20%
BIIB Biogen	0.18%
INCY Incyte	17.80%
NBIX Neurocrine Biosciences	4.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALNY Alnylam Pharmaceuticals	2,230	130.39 million	128.82 million	Optionable
BIIB Biogen	7,605	146.53 million	146.26 million	Optionable
INCY Incyte	2,617	193.57 million	159.12 million	Optionable
NBIX Neurocrine Biosciences	1,800	98.97 million	94.71 million	Optionable

NBIX, ALNY, BIIB, and INCY Headlines

Recent News About These Companies

Pallas Capital Advisors LLC Reduces Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

June 14, 2025 | marketbeat.com

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Given Average Recommendation of "Moderate Buy" by Brokerages

June 14, 2025 | marketbeat.com

Neurocrine Biosciences' SWOT analysis: biotech stock balances Ingrezza success with pipeline potential

June 14, 2025 | investing.com

Stanley Laman Group Ltd. Lowers Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

June 13, 2025 | marketbeat.com

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Tobam

June 13, 2025 | marketbeat.com

Assenagon Asset Management S.A. Buys 367,315 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

June 13, 2025 | marketbeat.com

Handelsbanken Fonder AB Boosts Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

June 13, 2025 | marketbeat.com

Davis Investment Partners LLC Purchases New Shares in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

June 12, 2025 | marketbeat.com

Cantor Fitzgerald Weighs in on NBIX FY2026 Earnings

June 12, 2025 | americanbankingnews.com

SG Americas Securities LLC Grows Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

June 11, 2025 | marketbeat.com

Neurocrine Biosciences, Inc.: Neurocrine Biosciences Appoints Lewis Choi as Chief Information Officer

June 10, 2025 | finanznachrichten.de

Analysts Issue Forecasts for NBIX FY2026 Earnings

June 10, 2025 | marketbeat.com

Congress Asset Management Co. Acquires New Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

June 10, 2025 | marketbeat.com

Neurocrine Biosciences Appoints Lewis Choi as Chief Information Officer | NBIX stock news

June 9, 2025 | gurufocus.com

Neurocrine Biosciences Appoints Lewis Choi as Chief Information Officer | NBIX Stock News

June 9, 2025 | gurufocus.com

Neurocrine Biosciences (NBIX) Appoints Lewis Choi as CIO | NBIX Stock News

June 9, 2025 | gurufocus.com

Neurocrine Biosciences names new Chief Information Officer

June 9, 2025 | investing.com

Neurocrine Biosciences Appoints Lewis Choi as Chief Information Officer

June 9, 2025 | prnewswire.com

Nxera Pharma earns $15m payment as first patient in schizophrenia drug trial is dosed by Neurocrine Biosciences

June 6, 2025 | cambridgeindependent.co.uk

Guggenheim Maintains Buy Rating on Neurocrine Biosciences Following Investor Meeting

June 6, 2025 | msn.com

Wealth Enhancement Advisory Services LLC Increases Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

June 6, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NBIX, ALNY, BIIB, and INCY Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

$308.71 -0.07 (-0.02%)

Closing price 06/17/2025 04:00 PM Eastern

Extended Trading

$322.97 +14.26 (+4.62%)

As of 06/17/2025 06:36 PM Eastern

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Biogen NASDAQ:BIIB

$126.56 -4.48 (-3.42%)

Closing price 06/17/2025 04:00 PM Eastern

Extended Trading

$126.49 -0.07 (-0.05%)

As of 04:27 AM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Incyte NASDAQ:INCY

$68.81 -2.41 (-3.38%)

Closing price 06/17/2025 04:00 PM Eastern

Extended Trading

$69.50 +0.69 (+1.00%)

As of 04:13 AM Eastern

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Neurocrine Biosciences NASDAQ:NBIX

$124.88 -0.12 (-0.10%)

Closing price 06/17/2025 04:00 PM Eastern

Extended Trading

$123.74 -1.15 (-0.92%)

As of 06/17/2025 04:43 PM Eastern

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time